To receive important alerts and updates from Gold Coast Primary Health Network, please submit the form below.
To receive important alerts and updates from Gold Coast Primary Health Network, please submit the form below.
Almost all Queensland children will experience at least one RSV infection by the time they turn two, with the virus the most common cause of hospitalisations among infants and young children. The highly contagious virus attacks the lungs and can have a potentially significant impact on infants and young children, as well as their families.
The Queensland Paediatric Respiratory Syncytial Virus Prevention (QPRSVP) Program will provide free Respiratory Syncytial Virus (RSV) immunisation to eligible Queensland newborn babies, infants and young children. The QPRSVP Program will use Nirsevimab (brand name Beyfortus®). Approved for use in infants and young children in Australia by the Therapeutic Goods Administration (TGA) in November 2023, Nirsevimab is a long-acting monoclonal antibody that provides infants and young children protection against RSV for at least 5 months and has shown to be up to 80 per cent effective in decreasing infant hospitalisations related to RSV.
Nirsevimab will be available at all Queensland birthing hospitals (public and private) for newborn babies from 15 April 2024.
Other immunisation providers will be able to access Nirsevimab via a special-order process, commencing from 1 May 2024. More information on this process will be made available prior to this date.
For further information on the QPRSVP Program, a full list of eligible infants and young children, and information on how to order please click here.
To view the ATAGI statement on Nirsevimab 2024, click here.
So we can provide you with the most accurate information,
please tell us a little more about yourself
